63 related articles for article (PubMed ID: 30603135)
1. Activation of EGFR-DNA-PKcs pathway by IGFBP2 protects esophageal adenocarcinoma cells from acidic bile salts-induced DNA damage.
Zhou Z; Lu H; Zhu S; Gomaa A; Chen Z; Yan J; Washington K; El-Rifai W; Dang C; Peng D
J Exp Clin Cancer Res; 2019 Jan; 38(1):13. PubMed ID: 30626422
[TBL] [Abstract][Full Text] [Related]
2. Methylation Biomarker Panel Performance in EsophaCap Cytology Samples for Diagnosing Barrett's Esophagus: A Prospective Validation Study.
Wang Z; Kambhampati S; Cheng Y; Ma K; Simsek C; Tieu AH; Abraham JM; Liu X; Prasath V; Duncan M; Stark A; Trick A; Tsai HL; Wang H; He Y; Khashab MA; Ngamruengphong S; Shin EJ; Wang TH; Meltzer SJ
Clin Cancer Res; 2019 Apr; 25(7):2127-2135. PubMed ID: 30670490
[TBL] [Abstract][Full Text] [Related]
3. Timeline and location of recurrence following successful ablation in Barrett's oesophagus: an international multicentre study.
Sami SS; Ravindran A; Kahn A; Snyder D; Santiago J; Ortiz-Fernandez-Sordo J; Tan WK; Dierkhising RA; Crook JE; Heckman MG; Johnson ML; Lansing R; Ragunath K; di Pietro M; Wolfsen H; Ramirez F; Fleischer D; Wang KK; Leggett CL; Katzka DA; Iyer PG
Gut; 2019 Aug; 68(8):1379-1385. PubMed ID: 30635408
[TBL] [Abstract][Full Text] [Related]
4. Expanding beyond endoscopy: A review of non-invasive modalities in Barrett's esophagus screening and surveillance.
Shahsavari D; Kudaravalli P; Yap JEL; Vega KJ
World J Gastroenterol; 2022 Aug; 28(32):4516-4526. PubMed ID: 36157931
[TBL] [Abstract][Full Text] [Related]
5. SOX17-mediated MALAT1-miR-199a-HIF1α axis confers sensitivity in esophageal squamous cell carcinoma cells to radiotherapy.
Yun Y; Zhang Y; Xu Q; Ou Y; Zhou X; Lu Z
Cell Death Discov; 2022 May; 8(1):270. PubMed ID: 35614065
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive RNA dataset of tissue and plasma from patients with esophageal cancer or precursor lesions.
Schoofs K; Philippron A; Avila Cobos F; Koster J; Lefever S; Anckaert J; De Looze D; Vandesompele J; Pattyn P; De Preter K
Sci Data; 2022 Mar; 9(1):86. PubMed ID: 35288573
[TBL] [Abstract][Full Text] [Related]
7. Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progression.
Maslyonkina KS; Konyukova AK; Alexeeva DY; Sinelnikov MY; Mikhaleva LM
Cancer Med; 2022 Jan; 11(2):447-478. PubMed ID: 34870375
[TBL] [Abstract][Full Text] [Related]
8. Screening for Barrett's Oesophagus: Are We Ready for it?
Yusuf A; Fitzgerald RC
Curr Treat Options Gastroenterol; 2021; 19(2):321-336. PubMed ID: 33746508
[TBL] [Abstract][Full Text] [Related]
9. Circulating MicroRNAs in Relation to Esophageal Adenocarcinoma Diagnosis and Survival.
Petrick JL; Pfeiffer RM; Liao LM; Abnet CC; Wu X; Gammon MD; Vaughan TL; Cook MB
Dig Dis Sci; 2021 Nov; 66(11):3831-3841. PubMed ID: 33403483
[TBL] [Abstract][Full Text] [Related]
10. Extracellular miRNAs for the Management of Barrett's Esophagus and Esophageal Adenocarcinoma: A Systematic Review.
Inokuchi K; Ochiya T; Matsuzaki J
J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33396321
[TBL] [Abstract][Full Text] [Related]
11. The Diagnostic and Prognostic Value of a Liquid Biopsy for Esophageal Cancer: A Systematic Review and Meta-Analysis.
Matsushita D; Arigami T; Okubo K; Sasaki K; Noda M; Kita Y; Mori S; Uenosono Y; Ohtsuka T; Natsugoe S
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33096708
[TBL] [Abstract][Full Text] [Related]
12. To BE or not to BE: non-invasive screening for Barrett's esophagus, dysplasia and adenocarcinoma.
Shah AK; Joshi V; Hartel G; Barbour AP; Hill MM
Transl Gastroenterol Hepatol; 2019; 4():31. PubMed ID: 31231698
[No Abstract] [Full Text] [Related]
13. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis.
Leidner RS; Ravi L; Leahy P; Chen Y; Bednarchik B; Streppel M; Canto M; Wang JS; Maitra A; Willis J; Markowitz SD; Barnholtz-Sloan J; Adams MD; Chak A; Guda K
Genes Chromosomes Cancer; 2012 May; 51(5):473-9. PubMed ID: 22302717
[TBL] [Abstract][Full Text] [Related]
14. Circulating microRNA expression profiling revealed miR-92a-3p as a novel biomarker of Barrett's carcinogenesis.
Fassan M; Realdon S; Cascione L; Hahne JC; Munari G; Guzzardo V; Arcidiacono D; Lampis A; Brignola S; Dal Santo L; Agostini M; Bracon C; Maddalo G; Scarpa M; Farinati F; Zaninotto G; Valeri N; Rugge M
Pathol Res Pract; 2020 May; 216(5):152907. PubMed ID: 32131978
[TBL] [Abstract][Full Text] [Related]
15. Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma.
Slaby O; Srovnal J; Radova L; Gregar J; Juracek J; Luzna P; Svoboda M; Hajduch M; Ehrmann J
Carcinogenesis; 2015 May; 36(5):521-7. PubMed ID: 25784377
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Review of Esophageal MicroRNA Markers for Diagnosis and Monitoring of Barrett's Esophagus.
Mallick R; Patnaik SK; Wani S; Bansal A
Dig Dis Sci; 2016 Apr; 61(4):1039-50. PubMed ID: 26572780
[TBL] [Abstract][Full Text] [Related]
17. A review of the current understanding and clinical utility of miRNAs in esophageal cancer.
Sakai NS; Samia-Aly E; Barbera M; Fitzgerald RC
Semin Cancer Biol; 2013 Dec; 23(6 Pt B):512-21. PubMed ID: 24013023
[TBL] [Abstract][Full Text] [Related]
18. Circulating miRNAs in patients with Barrett's esophagus, high-grade dysplasia and esophageal adenocarcinoma.
Pavlov K; Kluiver J; Meijer C; Boersma-van Ek W; Kruyt FAE; Karrenbeld A; Kleibeuker JH; Peters FTM; van den Berg A
J Gastrointest Oncol; 2018 Dec; 9(6):1150-1156. PubMed ID: 30603135
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
